Full Breakdown
China’s Aging Demographic Reshapes Sector Outlook, Goldman Sachs Predicts
6/24/2026, 9:39:24 PM
Core Forecast: Aging Drives Winners and Losers in Chinese Economy
Goldman Sachs released a report on Monday projecting that the rapid aging of Hong Kong and mainland China will create stark sectoral divergences. By 2050, Hong Kong is expected to rank first and mainland China eighth among the world’s most aged economies, up from 11th and 26th respectively in 2023. The analysis identifies pharmaceutical and biotechnology firms as the most likely beneficiaries, while automobile manufacturers and technology-hardware producers are expected to encounter heightened headwinds.
Background: China’s Accelerating Demographic Shift
The report bases its projections on each country’s old-age dependency ratio—the share of people aged 65 and over relative to the working-age population—and fertility rates. The ratio, the share of people aged 65+ relative to the working-age population, is projected to rise sharply in China and Hong Kong. Alongside Hong Kong and China, South Korea, Japan, Poland, Spain, Italy, Germany, Austria and Portugal are projected to remain or enter the top-10 list of aging economies by mid-century.
Data & Statistics
- 2023 old-age dependency rankings: Hong Kong 11th, mainland China 26th.
- 2050 projected rankings: Hong Kong 1st, mainland China 8th.
- Countries projected in the 2050 top-10: Hong Kong, China, South Korea, Japan, Poland, Spain, Italy, Germany, Austria, Portugal.
- The analysis highlights four companies with the strongest demographic-driven demand outlook through 2030.
Key Companies Highlighted
Goldman Sachs rates the following as top-buy candidates: Bluestar Adisseo – a Shanghai-listed animal-nutrition additive maker; WuXi XDC Cayman – a pharmaceutical contract-drug developer listed in Hong Kong; Sichuan Kelun-Biotech Biopharmaceutical – an oncology-focused biotech listed in Hong Kong; and Zai Lab – an oncology developer also traded in Hong Kong.
Why It Matters: Sectoral Implications
An expanding elderly population is expected to boost demand for healthcare products and services, positioning pharma and biotech firms for revenue growth. The demographic shift raises concerns about future productivity and a widening gap between working and retired populations. Conversely, a shrinking working-age base may suppress consumer spending on automobiles and reduce demand for technology hardware, creating “fiercer headwinds” for those sectors. Investors are therefore advised to reallocate capital toward companies poised to meet rising medical needs.
Official Statements & Responses
Goldman Sachs analysts note that healthcare will see the strongest demographic demand from ageing, underscoring the sector’s central role in the projected economic shift. The report recommends focusing on firms with pipelines aligned to chronic-disease treatment and animal-nutrition, while cautioning that discretionary-spending sectors could grow slower as the labor pool contracts.
Verbatim Quotes
> “Healthcare ... will see the strongest demographic demand from ageing,” — Goldman Sachs analyst
What’s Next: Investment Outlook to 2030
Investors should monitor the highlighted firms as demand materializes through 2030. Market participants are watching the sectoral rebalancing as demographic data continue to evolve.
